Menstrual Blood Emerges as a Promising Alternative for HPV Screening
Could menstrual blood be the key to revolutionizing how we screen for human papillomavirus (HPV)? A groundbreaking study conducted in China suggests that utilizing menstrual blood for HPV testing may serve as a non-invasive substitute for traditional cervical screenings. Researchers have found that when women collect their own menstrual blood, the diagnostic accuracy for identifying high-grade cervical lesions is on par with samples collected by healthcare professionals.
This extensive cross-sectional study involved 3,068 women aged between 20 and 54 years, all of whom had regular menstrual cycles. The participants were drawn from four urban and three rural communities within Hubei Province and were enrolled between 2021 and 2025. Each woman provided three different sample types: menstrual blood gathered using a sterile "minipad" affixed to a sanitary pad, a clinician-collected cervical sample for HPV analysis, and cytology samples. Those who tested positive for HPV were subsequently referred for colposcopy and biopsy to confirm the presence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+), which is the main clinical endpoint of the study.
Menstrual Blood Testing Shows Similar Results to Clinician-Collected Samples
The findings revealed that the sensitivity of HPV testing using menstrual blood was an impressive 94.7% for detecting CIN2+, which closely aligned with the 92.1% sensitivity found in clinician-collected samples. While the specificity was marginally lower for the minipad method at 89.1%, compared to 90.0% for the clinician-collected samples, both methods exhibited identical negative predictive values of 99.9%. This indicates a strong level of reassurance for patients when they receive negative results. Additionally, the positive predictive value and referral efficiency were comparable between the two sampling techniques.
HPV is a leading cause of cervical cancer, and screening initiatives have made a significant impact on reducing its incidence globally. However, various barriers—such as discomfort during exams, societal stigma, and limited access to healthcare facilities—often hinder participation in these vital screenings. Researchers propose that the ability to collect samples at home using menstrual blood could enhance screening rates, particularly among underserved populations who may struggle to access traditional healthcare services.
Transforming the Future of Cervical Cancer Screening with Menstrual Blood Testing
The study also examined the potential for integrating digital technology, allowing participants to receive their results and follow-up guidance through a mobile application. This innovation underscores the practicality of merging self-sampling methods with telehealth support. Nevertheless, the authors of the study caution that due to its observational nature, further research is necessary before this approach can be widely adopted. It will be crucial to conduct prospective trials and validate the methodology across varied populations to explore how menstrual blood testing might fit into current screening practices.
If these findings are confirmed, this approach could signify a transformative shift towards more patient-centered strategies for cervical cancer prevention, complementing traditional clinician-based screenings while alleviating some of the logistical and psychological hurdles that currently deter participation.
Reference:
Xun T et al. Testing menstrual blood for human papillomavirus during cervical cancer screening in China: cross-sectional population-based study. BMJ. 2026; 392:e084831.
Author:
All articles are available under the Creative Commons Attribution-Non Commercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/).
